News

Strongbridge Biopharma has entered into an agreement for $50 million in credit and $3 million in equity investment with the healthcare-focused firm CRG to meet the demand for Keveyis (dichlorphenamide) and advance the development of its major therapeutic candidate Recorlev (levoketoconazole). Recorlev is an investigational cortisol synthesis inhibitor under development for the…

Researchers found that unlike tumors localized in the pituitary gland that increase production of the hormone underlying Cushing’s syndrome, no mutations in USP8 were detected in tumors that induce the disease but are localized outside of the gland. This condition is known as ectopic ACTH secretion syndrome (EAS), or ectopic Cushing’s…

The multicenter, international Phase 3 SONICS study testing the safety and effectiveness of Strongbridge Biopharma’s therapy candidate Recorlev (levoketoconazole) for endogenous Cushing’s syndrome has reached its goal of enlisting 90 participants, which completes the enrollment phase. Due to strong interest in the study, a…

The Cushing’s Support and Research Foundation (CSRF) is calling attention to three books of potential interest to Cushing’s Disease patients and to healthcare providers who treat the relatively rare endocrine disorder. In Cushing’s Disease, the adrenal glands release too much of the hormone cortisol into the body for long periods…

Ortho Clinical Diagnostics, a producer of in vitro diagnostics, has announced that Ortho’s Vitros Immunodiagnostic Products Insulin Reagent and Calibrators have received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The insulin assay is part of a comprehensive diabetes…

A new Phase 3 clinical trial (NCT02697734) is actively recruiting Cushing’s disease patients in several countries to test the safety and effectiveness of the investigational therapy osilodrostat (LCI699). The 48-week, multicenter, randomized, double-blind, placebo-controlled study is sponsored by Novartis Pharmaceuticals. Estimated enrollment is 69 patients at 26 locations…

The recent identification of genetic mutations linked to Cushing disease (CD) and its unbalanced molecular mechanisms has opened new potential therapeutic avenues for an illness with a large unmet medical need. In the study, “Recent advances in understanding Cushing disease: resistance to…

Signifor (pasireotide), an approved therapy for Cushing’s disease, has shown promise as a long-term treatment for some patients with the disease, according to results of an extension study of a Phase 3 clinical trial (NCT00434148). These findings were published recently…

Aggressive adrenocortical carcinomas differ from tumors linked to Cushing’s syndrome in the density of blood and lymph vessels, according to a research team at Portugal’s University of Porto. Their study, “Angiogenesis and Lymphangiogenesis in the Adrenocortical Tumors,” appeared in the journal Pathology & Oncology Research. It offers insights into the…

Mutations in a gene called CABLES1 might contribute to pituitary tumor growth in people with Cushing’s disease, according to a study that suggests the gene normally acts as a pituitary tumor suppressor. The study, “Loss-of-function mutations in the…